Sounds very precise Eoganacht.  Of the 4 Nonresponders at 90 days, that includes 1 patient who passed away before 90 days assessment and had a high  chance of being CR given this patient had a negative urine cytology at 30 days.  Technically speaking results should be out of 22 patients, and 4 who only got a second Optimized dose should be counted separately IMo.  Results are impressive, not 100% CR, but still impressive given the novelty of a One and Done treatment ( plus a One and Done Maintenance treatment at 6 months).  Far better than any single agent I've seen and with way less treatments and side effects.  For sure we still need more data to finalize the numbers, but I can easily see 65% or even 70-80% CR at 90 days with with around 35-45% CR at 15 months.  A potential New Gold Standard in the making.All IMO

 

Eoganacht wrote:I think I finally understand the data for the optimized patients. If I got anything wrong please correct me.

In the last newsletter there were 18 patients who had received an optimized treatment.

The 90 day data for those 18 patients was as follows:

44% CR (8 patients)
11% partial response (2 patients)
39% pending (7 patients)
6% no response (1 patient) 

We were waiting to find out what happened to those 7 pending patients. Would they also be CR at 90 days? Since then 5 more patients have been treated so now there are 23 patients with an optimized treatment and since there are now 3 patients pending, 2 of the 5 reached 90 days so there are 9 more patients at the 90 day mark than there were at the time of the last newsletter. Here are the results for the 23 optimized patients.

The 90 day data for the current 23 optimized patients is as follows:

52.2% CR (12 patients)
17.4% partial response (4 patients)
13 % pending (3 patients)
The news release does not explicitly tell us how many non-responders there were, but 23-19=4 therefore:
17% no response (4 patients)

Of the 9 patients who reached 90 days since the last report 
44% CR (4 patients)
22% partial response (2 patients)
33% no response (3 patients)

As the news release makes explicit there is still the potential of 82.6 CR at 90 days for the 23 optimized patients (52.2% CR + 17.4% PR + 13% pending)